Charles River Laboratories International, Inc. (CRL) $233.41
Charles River Laboratories scorches the charts, but with an RSI of 84.3, the oxygen gets thin for new buyers.
52-wk High $237.86
📌 Investment Snapshot
- Current price $233.41 sits 95% up the 52-week range.
- Latest Q1 revenue $996M with EPS $-0.30.
- 1-month return of +25.3% reflects aggressive momentum.
- Consensus target of $220.67 implies 5.5% downside.
CRL exhibits extreme momentum, yet the technical setup demands patience. We advise waiting for a consolidation phase before initiating new long positions.
| 📍 Entry Zone | $193.86 or below | 🛑 Stop-Loss | $179.91 |
| 📋 Adjust If | Price reclaims $237.86 with 1.5x volume. | ||
The Investment Case — Why Now?
Charles River Laboratories recently staged a parabolic move, driven by strong sector sentiment and institutional accumulation. The stock now trades significantly above its 50-day and 200-day moving averages, reflecting a market that has priced in perfection.
However, the valuation disconnect creates a precarious setup. With the stock trading above the mean analyst target of $220.67, the risk-to-reward profile tilts toward a correction rather than further expansion.
🤔 Does the current momentum justify chasing a stock trading 5% above analyst consensus?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
📈 Price Action & Technicals
Golden Cross
Outside VA
Buy-side at $182.51
The RSI at 84.3 screams overbought, signaling an imminent mean reversion. ADX at 54 confirms a powerful trend, but parabolic moves often precede sharp corrections.
Unfilled bullish FVG zones at $227.81 and $217.19 provide clear downside targets for a retest. These zones represent liquidity gaps that likely attract price action during a pull-back.
The current price sits well above the VWAP of $179.91, indicating a stretched valuation relative to the long-term cost basis. The stock trades outside the Value Area High of $193.86, confirming the current deviation.
Volume ratio remains muted at 0.99x, suggesting the recent rally lacks significant institutional conviction at these elevated levels. This divergence between price and volume warns of a potential trap.
Technical confluence scores 80/100, but the overbought RSI overrides the trend strength. We prioritize capital preservation over chasing a blow-off top.
🤔 With the RSI at 84, are you prepared for a mean reversion, or do you expect the breakout to hold?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| CRL | Charles River | N/A |
| SPY | S&P 500 | 22.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $996M | $-0.30 | N/A |
| Q4 2025 | $994M | $-5.57 | N/A |
Free cash flow remains constrained at $0.0B, limiting the company’s ability to aggressively fund growth without debt.
Earnings volatility persists, with the company struggling to maintain consistent profitability over the last two quarters.
🚀 Growth Drivers — What Moves the Stock
- Research Outsourcing 🟡 Priced In — Increased demand for outsourced drug discovery services provides a steady revenue tailwind.
🤔 Can Charles River maintain margins if the broader biotech funding environment cools?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 3,859 |
| FMR, LLC | 3,456 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| FOSTER JAMES C | Director | 2026-06-29 | Sale | 75000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 10.4% | 5.1 |
⚠ Key Risk Factors
~$1.5B impact
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $265.00 | $220.67 | $135.00 | 15 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Morgan Stanley | Overweight | N/A | 2026-07-09 | main |
Analysts remain bullish, but the current price has outpaced the average target, suggesting potential downgrades or target revisions.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong institutional backing
- Dominant market share in research services
📊 Base Case
The stock consolidates near current levels to digest recent gains.
🐻 Bear Case
- Overbought technicals
- Lack of consistent profitability
🎯 Investor Action Plan — By Profile
Avoid entry until the RSI cools below 60 and price tests the $217 support level.
Wait for a pullback to the $190-$200 range to improve the risk-reward ratio.
Maintain existing positions, but avoid adding new capital at these overextended levels.
❓ Investor FAQ — People Also Ask
Q: Why is the verdict WAIT despite the strong trend?
The RSI of 84.3 indicates the stock is severely overbought, and the price currently exceeds the consensus analyst target.
Q: What is the key level to watch?
The $217.19 FVG zone serves as the primary support level for a potential retest.
Q: Is the short interest a concern?
With 10.4% short interest, the stock is susceptible to volatility, but it does not justify buying at these extreme technical levels.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Always conduct your own due diligence.
All active positions and their real-time performance are tracked on our Investment Log.
#CRL #CharlesRiver #StockMarket #Investing #Healthcare #TechnicalAnalysis #Trading #WallStreet